Literature DB >> 8614278

Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand.

J Romero1, E García-Palomero, S Y Lin, J A Ramos, A Makriyannis, J J Fernández-Ruiz.   

Abstract

Recent evidence has demonstrated that arachidonylethanolamide ("anandamide", AEA), the major endogenous ligand of CB1 receptors, inhibits motor behavior in rats, as does (-)delta 9-tetrahydrocannabinol (THC), the prototypical tricyclic cannabinoid derived from Cannabis sativa preparations. However, its effects were of shorter duration, as compared to THC, likely due to its rapid breakdown by an amidase activity. The present work has been designed to examine the motor effects of AM356(R-methanandamide), an analog of AEA that possesses higher metabolic stability to amidase hydrolysis. We have studied the dose-response and time-course effects of R-methanandamide, i.p. administered, on ambulatory activity, frequency of stereotypy and time spent in inactivity measured in an open-field test. Results were as follows. R-Methanandamide, as THC and AEA, inhibited motor behavior. Thus, it decreased ambulation and stereotypy and increased the time spent in inactivity, usually in a dose-related manner, 10 min after administration. However, the motor deficit caused by the highest dose of R-methanandamide was usually more pronounced than that caused by a similar dose of AEA. These inhibitory effects persisted 30 min after the administration of R-methanandamide, as occurred with AEA and THC. Interestingly, at 60 min after administration, the effects of AEA disappeared, likely because of its breakdown to arachidonic acid and ethanolamine, but this did not occur with R-methanandamide whose effects persisted even until 180 min after treatment as occurred with THC. In summary, R-methanandamide inhibits motor behavior in a manner (its effects were persistent) that resembles the effects of THC rather than the effects of AEA (its effects were of rapid onset but shorter duration). This fact supports the use of R-methanandamide as a valuable tool for studying the physiological roles of the anandamidergic system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8614278     DOI: 10.1016/0024-3205(96)00086-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Cannabinoid receptor and WIN-55,212-2-stimulated [35S]GTP gamma S binding and cannabinoid receptor mRNA levels in the basal ganglia and the cerebellum of adult male rats chronically exposed to delta 9-tetrahydrocannabinol.

Authors:  J Romero; F Berrendero; L García-Gil; J A Ramos; J J Fernández-Ruiz
Journal:  J Mol Neurosci       Date:  1998-10       Impact factor: 3.444

2.  Cannabinoid conditioned reward and aversion: behavioral and neural processes.

Authors:  Jennifer E Murray; Rick A Bevins
Journal:  ACS Chem Neurosci       Date:  2010-03-10       Impact factor: 4.418

3.  The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys.

Authors:  Zuzana Justinova; Marcello Solinas; Gianluigi Tanda; Godfrey H Redhi; Steven R Goldberg
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.167

4.  Evaluation of the role of striatal cannabinoid CB1 receptors on movement activity of parkinsonian rats induced by reserpine.

Authors:  Hadi Fathi Moghaddam; Mohammad Javad Khodayar; Seyed Mohammad Zarei Abarghouei; Mehdi Shafiee Ardestani
Journal:  Saudi Pharm J       Date:  2010-05-31       Impact factor: 4.330

5.  Methanandamide blocks amphetamine-induced behavioral sensitization in rats.

Authors:  Bruce A Rasmussen; Ellen M Unterwald; Jae K Kim; Scott M Rawls
Journal:  Eur J Pharmacol       Date:  2009-10-30       Impact factor: 4.432

6.  Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors.

Authors:  Miriam Melis; Marco Pistis; Simona Perra; Anna Lisa Muntoni; Giuliano Pillolla; Gian Luigi Gessa
Journal:  J Neurosci       Date:  2004-01-07       Impact factor: 6.167

7.  Development of novel tail-modified anandamide analogs.

Authors:  Fenmei Yao; Chen Li; Subramanian K Vadivel; Anna L Bowman; Alexandros Makriyannis
Journal:  Bioorg Med Chem Lett       Date:  2008-07-31       Impact factor: 2.823

8.  Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction.

Authors:  Zachary Newman; Priya Malik; Tse-Yu Wu; Christopher Ochoa; Nayantara Watsa; Clark Lindgren
Journal:  Eur J Neurosci       Date:  2007-04-04       Impact factor: 3.386

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.